Publikationer Helena Jernberg Wiklund

Publikationer i DiVA

Publikationer i PubMed

Ett urval av våra publikationer

Nylund P, Atienza P.rraga A, Hagl.f J, De Bruyne E, Menu E, Garrido-Zabala B, Ma A, Jin J, Öberg F, Vanderkerken K, Kalushkova A, Jernberg-Wiklund H. A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. Cell Death Dis. 2021,12(2):167.
Pressmeddelande: Metabolism-förändring bakom minskad tillväxt av cancerceller.
Alzrigat M, Jernberg-Wiklund H, Licht JD. Targeting EZH2 in Multiple Myeloma- Multifaceted Anti-Tumor Activity. Epigenomes. 2018, 2(3):16.
Alzrigat M, P.rraga AA, Majumder MM, Ma A, Jin J, .Österborg A, Nahi H, Nilsson K, Heckman CA, Öberg F, Kalushkova A, Jernberg-Wiklund H. The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget. 2017, 8(61):103731-103743.
Alzrigat M, Parraga AA, Jernberg-Wiklund H. Epigenetics in multiple myeloma: From mechanisms to therapy. Semin Cancer Biol. 2018, 51:101-115.
Alzrigat M, Jernberg-Wiklund H. The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis. 2017, 4(2): e1529.
Alzrigat M, Parraga AA, Agarwal P, Zureigat H, Österborg A, Nahi H, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget. 2016 Dec 30.
Agarwal P, Alzrigat M, Parraga AA, Enroth S, Singh U, Ungerstedt J, Österborg A, Brown PJ, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget. 2016 Jan 7.
Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, and Vanderkerken K. Targeting the IGF-1R using picropodophyllin (PPP) in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer. 2007, 121(8):1857-61.